Marinomed Biotech AG logo

MARI - Marinomed Biotech AG News Story

€124 -1.0  -0.8%

Last Trade - 07/05/21

Sector
Healthcare
Size
Small Cap
Market Cap £159.2m
Enterprise Value £162.3m
Revenue £7.07m
Position in Universe 662nd / 1050

BRIEF-Marinomed Biotech says its nasal spray showed significant efficacy in preventing COVID-19

Fri 19th February, 2021 12:52pm
Feb 19 (Reuters) - 
    * MARINOMED BIOTECH SAYS ITS IOTA-CARRAGEENAN NASAL SPRAY
SHOWED
SIGNIFICANT EFFICACY IN THE PREVENTION OF COVID-19 IN HOSPITAL
STAFF WHO MANAGE PATIENTS WITH THIS DISEASE

Source text for Eikon:  ID:nPexg7Rzga 
Further company coverage:  MARI.VI 

 (Reporting by Thomas Escritt)
 ((thomas.escritt@thomsonreuters.com; +49 30 2888 5217;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.